Push for consumer drug ads gets cool reception in Europe

Cassels, Alan
April 2002
CMAJ: Canadian Medical Association Journal;4/2/2002, Vol. 166 Issue 7, p946
Academic Journal
Focuses on consumer drug advertising in Europe. Proposed changes to European Commission (EC) legislation allowing drug companies to advertise AIDS, asthma, and diabetes medications to the public for a trial period; Way that direct-to-consumer drug advertising is illegal in most industrialized countries; Opposition of consumers to the proposal.


Related Articles

  • An Analytical Evaluation of Consumers' (North-West Indians) Opinion towards Pharmaceutical Advertisements. Garg, Avnish; Verma, Vikash K.; Kumar, Amit; Kumar, Arun; Pradeep; Nikunj; Vishal; Prabhakar; Singla, Rajeev K. // Indo Global Journal of Pharmaceutical Sciences;1/3/2013, Vol. 3 Issue 2, p134 

    According to the guidelines under Drug & Cosmetics Act and DCGI, India, every medicinal brand cannot be advertised except few like disprin, oral contraceptives like i-pill, and vitamin supplements like Revital etc. But it was observed that consumers are not well aware about it. So the current...

  • House DTC hearing blows black smoke. Kamp, John // Medical Marketing & Media;Jun2008, Vol. 43 Issue 6, p6 

    The article focuses on the issue of direct-to-consumer (DTC) prescription drug advertising in the U.S. It notes that some drug companies have been accused of airing false and misleading advertisements. The U.S. Congress soon will ban those advertisements to protect consumers. At the May 2008...

  • PhRMA gives DTC guidelines light retouch. Arnold, Matthew // Medical Marketing & Media;Jan2009, Vol. 44 Issue 1, p34 

    The article reports on the release of the revised version of the Pharmaceutical Research and Manufacturers of America's (PhRMA) Guiding Principles for Direct to Consumer Advertisements About Prescription Medicines. The version outlines that print and television (TV) advertisements for erectile...

  • PR View. Durand, Michael // Medical Marketing & Media;Jul2005, Vol. 40 Issue 7, p28 

    Reports on the introduction of the Pharmaceutical Advertising and Prudent Purchasing Act in the U.S. Provisions of the bill.

  • Drug Product Placements Flying Under FDA's Radar. Edwards, Jim // Brandweek;11/14/2005, Vol. 46 Issue 41, p14 

    This article focuses on issues concerning the legal aspects of prescription drug product placements in the U.S. as of November 2005. The Food and Drug Administration (FDA) has no specific rules on it, and its officials declined to comment. There were 166 mentions of prescription drug brands...

  • States Target DTC Advertising. Wechsler, Jill // Pharmaceutical Executive;Dec2001, Vol. 21 Issue 12, p23 

    Reports on the proposals made by state governments regarding direct-to-consumer (DTC) advertising of prescription medicines in the United States. How the bills address inappropriate prescribing and minimize interference in the doctor-patient relationship; Reason for the failure of state...

  • Pharmaceuticals Advertising: Overview. Griswold, Ann // Points of View: Pharmaceuticals Advertising;3/1/2016, p1 

    An overview of pharmaceuticals advertising is presented. Direct-to-consumer (DTC) advertising and prescription drug samples are discussed. Vocabulary such as "Disease awareness ad," "Reminder ad," and "Key opinion leaders" are defined. Particular focus is given to the increase in DTC advertising...

  • European drug ad furor. Silversides, Ann // CMAJ: Canadian Medical Association Journal;9/1/2009, Vol. 181 Issue 5, pE75 

    The article discusses the controversies surrounding the proposals of the European Commission (EC) that could weaken the ban on advertising prescription drugs to customers in Europe. It highlights the need to improve public information about prescription drugs. According to the article, the EC...

  • Pharmaceuticals in Europe. Taylor, David // BMJ: British Medical Journal (International Edition);3/16/91, Vol. 302 Issue 6777, p370 

    Reports the discussion document for the pharmaceutical sector released by the European Commission in Europe. Freedom in prescription; Aspiration to restrain public expenditure on pharmaceuticals; Decrease on the price of pharmaceutical products.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics